Author: laminar

29 May

Posted at 13:27h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Palma de Mallorca, May 30th 2015 –   Updated results of the ongoing Phase I/IIA clinical trial with 2OHOA in patients with advanced solid tumours, including malignant glioma (MIN-001-1203), were presented today in a poster discussion session at...

07 Apr

Posted at 13:31h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Palma de Mallorca, April 07, 2015 –   Laminar Pharma announced today that a key patent for the company, owned by the University of the Balearic Islands (UIB) and licensed in exclusive to Laminar Pharma, has...

04 Nov

Posted at 13:33h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Palma de Mallorca, November 04th, 2014 –   Laminar Pharma presented today at BIO-Europe 2014, the leading biotechnological event in Europe, held in Frankfurt (Germany) 3-5 November, the main highlights of its Phase I/IIA clinical trial with 2OHOA...

30 Oct

Posted at 13:35h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]“Junior Lab” is a pioneering project launched by the Balearic Islands Biotechnology and Biomedical Cluster (BIOIB) in collaboration with Laminar Pharma and several secondary and high school centers in the Mallorca.   The objective of...

25 Aug

Posted at 13:49h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Her Majesty the Queen Sofia of Spain has made today a private visit to the Laboratory of Molecular and Cellular Biomedicine of the University of the Balearic Islands. The research group, led by...

16 Jun

Posted at 13:50h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Laminar Pharma Scientific Advisory Board (SAB) has held a meeting today in Madrid were a group of leading scientist had discussed the molecular basis and mechanism of action of the novel MLT-based LP226A1,...

18 Dec

Posted at 13:54h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Laminar Pharma, empresa co-fundadora del Cluster Biotecnológico y Biomédico de las Illes Balears (BIOIB), recibe el Premio Onda Cero Mallorca de Ciencia e Investigación por sus avances científicos en el campo biomédico, especialmente...

10 Dec

Posted at 13:58h in Press, Sin categoría

  [vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]-> Laminar Pharma was selected as one of the 8 best European projects in the Health Care space by a prestigious panel of 28 directives of pharmaceutical companies and Venture Capital Funds specialized...

15 May

Posted at 14:00h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]After obtaining all required regulatory authorizations in the UK for the clinical study MIN-001-1203, Laminar Pharma confirmed the activation of the first site in Sutton, Surrey (UK), which will be recruiting participants from today....

13 Mar

Posted at 14:02h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]2OHOA is a new class of lipid regulator, multi-target anticancer drug for tumors with sphingomyelin metabolism alterations. It activates sphingomyelin synthase (SMS), a new and powerful potential anticancer drug target, which results in a specific...